NCT02097238 2020-05-19
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
10 trialsNCT02178241 2019-12-16
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00410553 2018-10-03
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00334893 2017-11-29
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00383760 2017-10-20
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
National Cancer Institute (NCI)
Phase 2 Completed
NCT00337129 2015-08-25
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00400829 2015-01-07
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00337077 2014-06-23
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00415324 2014-05-20
Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00047034 2013-01-07
E7389 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed